KL
Therapeutic Areas
Oncoinvent Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Radspherin | Peritoneal Metastases from Ovarian Cancer | Phase 2 |
Leadership Team at Oncoinvent
ØS
Øystein Soug
Chief Executive Officer
RA
Ramzi Amri
Chief Financial Officer
KM
Kari Myren
Chief Medical Officer
GH
Gro Hjellum
Chief Operating Officer
SB
Stian Brekke
Head of Regulatory Affairs
AA
Anne-Kirsti Aksnes
Chief Clinical Officer
AC
Anne Cecilie Alvik
Head of Quality Assurance / Board Member
KT
Kaja Tunhøvd Johansen
Head of Quality Control
GO
Gillies O’Bryan-Tear
Chairperson of the Board
IT
Ingrid Teigland Akay
Board Member